Kodak time 3 days trade same amount of contracts After Market will be rocket
emprendimientojtm
Posts
-
-
I will sell at $4
-
This stock will be on fire tomorrow they have many opportunity rocket
-
Good news here must be FDA approved ?
-
Good news here FDA approved
-
Tomorrow kodak its the past and this stock SNGX will be pump
-
Target $2 on monday
-
This stock will next ibio next week will keep this stock until Target $2
-
Same behavior of $TNXP this stock will 4x in monday will explode have preclinical vaccine for Covid 19 and strong other result , only need a University support
-
TNXP Stock: A Top COVID-19 Vaccine Play
Alex CarlsonJuly 23, 2020
There’s no denying the best sector for investors right now is the COVID-19 vaccine plays. We at Insider Financial have nailed quite a few this year, from Inovio Pharmaceuticals to Moderna to Vaxart and most recently with Heat Biologics. Now we are turning our attention to TNXP stock, a name that we have covered in the past and another Covid-19 vaccine player that has yet to make a huge move like Inovio, Moderna, Vaxart, and Heat Biologics, but soon will.The Importance Of T-Cells
The reason we like TNXP stock so much right now is the new evidence that is coming out regarding immunity to COVID-19. Evidence is emerging that T-cells, which can “remember” past infections and kill pathogens if they reappear, have a big influence on how long patients remain resistant to reinfection by Covid-19. The cells, whose size and complexity dwarf tiny antibodies, also appear to affect how well vaccines work and even the level of immunity in the community required to suppress new waves of disease.
People who recovered from Sars, the disease most closely related to Covid-19, in 2003 still show cellular immunity to that coronavirus 17 years later. T-cells, which circulate in the blood, might protect people who have been infected and recovered from the new coronavirus but have no detectable antibodies shortly thereafter. According to Al Edwards, associate professor at Reading University’s School of Pharmacy:
“T-cells are tasting the virus whereas the antibodies are feeling the virus. T-cells can promote antibody responses and antibody responses can promote a T-cell response. These two systems work together.”
TNXP Stock and Southern Research
TNXP stock is collaborating with Southern Research on a COVID-19 vaccine. The two have just expanded their collaboration focusing specifically on T cell immune responses to SARS-CoV-2 in volunteers who have recovered from the disease or who remain asymptomatic after exposure to COVID-19. Raj Kalkeri, Ph.D., MBA, a senior scientist in Southern Research’s Infectious Disease Research Group, said the study’s findings will shed new light on the role that T cells – a central part of the immune system – may play in the development of a vaccine against the novel coronavirus.
-
$TNXP the cheapest CoVid 19 vaccine will run tomorrow at $3 Penny Stocks To Buy Under $4: Tonix Pharmaceuticals Holding
We talked about Tonix Pharmaceuticals Holding (TNXP Stock Report) over the weekend. This came after TNXP had one of its most active days of the year. The only other day to outpace July 17th was earlier in the year in February. Thatâ€s when the penny stock saw a move to highs of $1.23 and traded more than 167 million shares. That was when the company announced a strategic collaboration with Southern Research to support the development of a vaccine, TNX-1800 to protect against COVID-19.
This month Tonix announced that it met its target enrollment of approximately 470 participants in a Phase 3 RELIEF trial of TNX-102 SL 5.6 mg. The treatment is in development as a non-opioid, centrally acting analgesic, taken daily at bedtime for the management of fibromyalgia. On the heels of that update, Tonix also announced a collaboration with Columbia University to study immune responses against COVID-19.
“This work may also guide the selection of appropriate individuals for COVID-19 vaccine trials, such as for Tonix's TNX-1800, based on a live replicating vector platform, which is designed to confer durable T cell immunity. It is also possible that new COVID-19 vaccines can be designed which will be tailored to individuals by precision medicine,” said Seth Lederman, M.D., President and Chief Executive Officer of Tonix. Keep in mind that the penny stock closed the week last week around $0.80 and has already started turning higher during premarket trading on Monday. Will this trend continue or is a pullback in store?
-
$TNXP the cheapest CoVid 19 vaccine will run tomorrow at $3 Penny Stocks To Buy Under $4: Tonix Pharmaceuticals Holding
We talked about Tonix Pharmaceuticals Holding (TNXP Stock Report) over the weekend. This came after TNXP had one of its most active days of the year. The only other day to outpace July 17th was earlier in the year in February. Thatâ€s when the penny stock saw a move to highs of $1.23 and traded more than 167 million shares. That was when the company announced a strategic collaboration with Southern Research to support the development of a vaccine, TNX-1800 to protect against COVID-19.
This month Tonix announced that it met its target enrollment of approximately 470 participants in a Phase 3 RELIEF trial of TNX-102 SL 5.6 mg. The treatment is in development as a non-opioid, centrally acting analgesic, taken daily at bedtime for the management of fibromyalgia. On the heels of that update, Tonix also announced a collaboration with Columbia University to study immune responses against COVID-19.
“This work may also guide the selection of appropriate individuals for COVID-19 vaccine trials, such as for Tonix's TNX-1800, based on a live replicating vector platform, which is designed to confer durable T cell immunity. It is also possible that new COVID-19 vaccines can be designed which will be tailored to individuals by precision medicine,” said Seth Lederman, M.D., President and Chief Executive Officer of Tonix. Keep in mind that the penny stock closed the week last week around $0.80 and has already started turning higher during premarket trading on Monday. Will this trend continue or is a pullback in store?
-
$TNXP the cheapest CoVid 19 vaccine will run tomorrow at $3 Penny Stocks To Buy Under $4: Tonix Pharmaceuticals Holding
We talked about Tonix Pharmaceuticals Holding (TNXP Stock Report) over the weekend. This came after TNXP had one of its most active days of the year. The only other day to outpace July 17th was earlier in the year in February. Thatâ€s when the penny stock saw a move to highs of $1.23 and traded more than 167 million shares. That was when the company announced a strategic collaboration with Southern Research to support the development of a vaccine, TNX-1800 to protect against COVID-19.
This month Tonix announced that it met its target enrollment of approximately 470 participants in a Phase 3 RELIEF trial of TNX-102 SL 5.6 mg. The treatment is in development as a non-opioid, centrally acting analgesic, taken daily at bedtime for the management of fibromyalgia. On the heels of that update, Tonix also announced a collaboration with Columbia University to study immune responses against COVID-19.
“This work may also guide the selection of appropriate individuals for COVID-19 vaccine trials, such as for Tonix's TNX-1800, based on a live replicating vector platform, which is designed to confer durable T cell immunity. It is also possible that new COVID-19 vaccines can be designed which will be tailored to individuals by precision medicine,” said Seth Lederman, M.D., President and Chief Executive Officer of Tonix. Keep in mind that the penny stock closed the week last week around $0.80 and has already started turning higher during premarket trading on Monday. Will this trend continue or is a pullback in store?
-
$TNXP the cheapest CoVid 19 vaccine will run tomorrow at $3 Penny Stocks To Buy Under $4: Tonix Pharmaceuticals Holding
We talked about Tonix Pharmaceuticals Holding (TNXP Stock Report) over the weekend. This came after TNXP had one of its most active days of the year. The only other day to outpace July 17th was earlier in the year in February. Thatâ€s when the penny stock saw a move to highs of $1.23 and traded more than 167 million shares. That was when the company announced a strategic collaboration with Southern Research to support the development of a vaccine, TNX-1800 to protect against COVID-19.
This month Tonix announced that it met its target enrollment of approximately 470 participants in a Phase 3 RELIEF trial of TNX-102 SL 5.6 mg. The treatment is in development as a non-opioid, centrally acting analgesic, taken daily at bedtime for the management of fibromyalgia. On the heels of that update, Tonix also announced a collaboration with Columbia University to study immune responses against COVID-19.
“This work may also guide the selection of appropriate individuals for COVID-19 vaccine trials, such as for Tonix's TNX-1800, based on a live replicating vector platform, which is designed to confer durable T cell immunity. It is also possible that new COVID-19 vaccines can be designed which will be tailored to individuals by precision medicine,” said Seth Lederman, M.D., President and Chief Executive Officer of Tonix. Keep in mind that the penny stock closed the week last week around $0.80 and has already started turning higher during premarket trading on Monday. Will this trend continue or is a pullback in store?
-
$TNXP the cheapest CoVid 19 vaccine will run tomorrow at $3 Penny Stocks To Buy Under $4: Tonix Pharmaceuticals Holding
We talked about Tonix Pharmaceuticals Holding (TNXP Stock Report) over the weekend. This came after TNXP had one of its most active days of the year. The only other day to outpace July 17th was earlier in the year in February. Thatâ€s when the penny stock saw a move to highs of $1.23 and traded more than 167 million shares. That was when the company announced a strategic collaboration with Southern Research to support the development of a vaccine, TNX-1800 to protect against COVID-19.
This month Tonix announced that it met its target enrollment of approximately 470 participants in a Phase 3 RELIEF trial of TNX-102 SL 5.6 mg. The treatment is in development as a non-opioid, centrally acting analgesic, taken daily at bedtime for the management of fibromyalgia. On the heels of that update, Tonix also announced a collaboration with Columbia University to study immune responses against COVID-19.
“This work may also guide the selection of appropriate individuals for COVID-19 vaccine trials, such as for Tonix's TNX-1800, based on a live replicating vector platform, which is designed to confer durable T cell immunity. It is also possible that new COVID-19 vaccines can be designed which will be tailored to individuals by precision medicine,” said Seth Lederman, M.D., President and Chief Executive Officer of Tonix. Keep in mind that the penny stock closed the week last week around $0.80 and has already started turning higher during premarket trading on Monday. Will this trend continue or is a pullback in store?
-
$TNXP the cheapest CoVid 19 vaccine will run tomorrow at $3 Penny Stocks To Buy Under $4: Tonix Pharmaceuticals Holding
We talked about Tonix Pharmaceuticals Holding (TNXP Stock Report) over the weekend. This came after TNXP had one of its most active days of the year. The only other day to outpace July 17th was earlier in the year in February. Thatâ€s when the penny stock saw a move to highs of $1.23 and traded more than 167 million shares. That was when the company announced a strategic collaboration with Southern Research to support the development of a vaccine, TNX-1800 to protect against COVID-19.
This month Tonix announced that it met its target enrollment of approximately 470 participants in a Phase 3 RELIEF trial of TNX-102 SL 5.6 mg. The treatment is in development as a non-opioid, centrally acting analgesic, taken daily at bedtime for the management of fibromyalgia. On the heels of that update, Tonix also announced a collaboration with Columbia University to study immune responses against COVID-19.
“This work may also guide the selection of appropriate individuals for COVID-19 vaccine trials, such as for Tonix's TNX-1800, based on a live replicating vector platform, which is designed to confer durable T cell immunity. It is also possible that new COVID-19 vaccines can be designed which will be tailored to individuals by precision medicine,” said Seth Lederman, M.D., President and Chief Executive Officer of Tonix. Keep in mind that the penny stock closed the week last week around $0.80 and has already started turning higher during premarket trading on Monday. Will this trend continue or is a pullback in store?
-
$TNXP the cheapest CoVid 19 vaccine will run tomorrow at $3 Penny Stocks To Buy Under $4: Tonix Pharmaceuticals Holding
We talked about Tonix Pharmaceuticals Holding (TNXP Stock Report) over the weekend. This came after TNXP had one of its most active days of the year. The only other day to outpace July 17th was earlier in the year in February. That’s when the penny stock saw a move to highs of $1.23 and traded more than 167 million shares. That was when the company announced a strategic collaboration with Southern Research to support the development of a vaccine, TNX-1800 to protect against COVID-19.
This month Tonix announced that it met its target enrollment of approximately 470 participants in a Phase 3 RELIEF trial of TNX-102 SL 5.6 mg. The treatment is in development as a non-opioid, centrally acting analgesic, taken daily at bedtime for the management of fibromyalgia. On the heels of that update, Tonix also announced a collaboration with Columbia University to study immune responses against COVID-19.
“This work may also guide the selection of appropriate individuals for COVID-19 vaccine trials, such as for Tonix's TNX-1800, based on a live replicating vector platform, which is designed to confer durable T cell immunity. It is also possible that new COVID-19 vaccines can be designed which will be tailored to individuals by precision medicine,” said Seth Lederman, M.D., President and Chief Executive Officer of Tonix. Keep in mind that the penny stock closed the week last week around $0.80 and has already started turning higher during premarket trading on Monday. Will this trend continue or is a pullback in store?
-
$TNXP will run tomorrow target $3 for Covid 19 vaccine Penny Stocks To Buy Under $4: Tonix Pharmaceuticals Holding
We talked about Tonix Pharmaceuticals Holding (TNXP Stock Report) over the weekend. This came after TNXP had one of its most active days of the year. The only other day to outpace July 17th was earlier in the year in February. That’s when the penny stock saw a move to highs of $1.23 and traded more than 167 million shares. That was when the company announced a strategic collaboration with Southern Research to support the development of a vaccine, TNX-1800 to protect against COVID-19.
This month Tonix announced that it met its target enrollment of approximately 470 participants in a Phase 3 RELIEF trial of TNX-102 SL 5.6 mg. The treatment is in development as a non-opioid, centrally acting analgesic, taken daily at bedtime for the management of fibromyalgia. On the heels of that update, Tonix also announced a collaboration with Columbia University to study immune responses against COVID-19.
“This work may also guide the selection of appropriate individuals for COVID-19 vaccine trials, such as for Tonix's TNX-1800, based on a live replicating vector platform, which is designed to confer durable T cell immunity. It is also possible that new COVID-19 vaccines can be designed which will be tailored to individuals by precision medicine,” said Seth Lederman, M.D., President and Chief Executive Officer of Tonix. Keep in mind that the penny stock closed the week last week around $0.80 and has already started turning higher during premarket trading on Monday. Will this trend continue or is a pullback in store?
-
$TNXP Penny Stocks To Buy Under $4: Tonix Pharmaceuticals Holding
We talked about Tonix Pharmaceuticals Holding (TNXP Stock Report) over the weekend. This came after TNXP had one of its most active days of the year. The only other day to outpace July 17th was earlier in the year in February. That’s when the penny stock saw a move to highs of $1.23 and traded more than 167 million shares. That was when the company announced a strategic collaboration with Southern Research to support the development of a vaccine, TNX-1800 to protect against COVID-19.
This month Tonix announced that it met its target enrollment of approximately 470 participants in a Phase 3 RELIEF trial of TNX-102 SL 5.6 mg. The treatment is in development as a non-opioid, centrally acting analgesic, taken daily at bedtime for the management of fibromyalgia. On the heels of that update, Tonix also announced a collaboration with Columbia University to study immune responses against COVID-19.
“This work may also guide the selection of appropriate individuals for COVID-19 vaccine trials, such as for Tonix's TNX-1800, based on a live replicating vector platform, which is designed to confer durable T cell immunity. It is also possible that new COVID-19 vaccines can be designed which will be tailored to individuals by precision medicine,” said Seth Lederman, M.D., President and Chief Executive Officer of Tonix. Keep in mind that the penny stock closed the week last week around $0.80 and has already started turning higher during premarket trading on Monday. Will this trend continue or is a pullback in store?
-
Penny Stocks To Buy Under $4: Tonix Pharmaceuticals Holding
We talked about Tonix Pharmaceuticals Holding (TNXP Stock Report) over the weekend. This came after TNXP had one of its most active days of the year. The only other day to outpace July 17th was earlier in the year in February. That’s when the penny stock saw a move to highs of $1.23 and traded more than 167 million shares. That was when the company announced a strategic collaboration with Southern Research to support the development of a vaccine, TNX-1800 to protect against COVID-19.
This month Tonix announced that it met its target enrollment of approximately 470 participants in a Phase 3 RELIEF trial of TNX-102 SL 5.6 mg. The treatment is in development as a non-opioid, centrally acting analgesic, taken daily at bedtime for the management of fibromyalgia. On the heels of that update, Tonix also announced a collaboration with Columbia University to study immune responses against COVID-19.
“This work may also guide the selection of appropriate individuals for COVID-19 vaccine trials, such as for Tonix's TNX-1800, based on a live replicating vector platform, which is designed to confer durable T cell immunity. It is also possible that new COVID-19 vaccines can be designed which will be tailored to individuals by precision medicine,” said Seth Lederman, M.D., President and Chief Executive Officer of Tonix. Keep in mind that the penny stock closed the week last week around $0.80 and has already started turning higher during premarket trading on Monday. Will this trend continue or is a pullback in store?
GEVO
GEVO
SMRT
ATNM
OPGN
SNGX
ATNM
ATNM
SNGX
TNXP
HEPA
TTOO
GNUS
PDSB
HTBX
IBIO
MBRX
NOVN
IMRN
TNXP